Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells


  • Presented in part at the annual meeting of the American Gastroenterology Association, in May 2004.

  • Potential conflict of interest: Nothing to report.


Phospholipase A2 IIA (PLA2IIA), which plays a crucial role in arachidonic acid metabolism and in inflammation, is upregulated under various pathological conditions, including in the gallbladder and gallbladder bile from patients with multiple cholesterol gallstones, in the liver and kidney of rats with cirrhosis, as well as in the colonic tissue of animals treated with a chemical carcinogen. The administration of ursodeoxycholic acid (UDCA) partially attenuated the PLA2IIA expression level in these different models. The aim of this study was to investigate the modulatory effect of UDCA on the PLA2IIA expression level at the cellular level. The HepG2 cells were selected to investigate the direct inhibitory effect of UDCA on PLA2IIA expression level. The proinflammatory cytokines (interleukin-6 and tumor necrosis factor α) -induced PLA2IIA expression in HepG2 cells was partially inhibited by the presence of UDCA in a dose-dependent fashion. The effect of UDCA on proinflammatory cytokines-induced PLA2IIA expression occurred at the transcriptional level. In addition, among the bile acids tested, this inhibitory effect was UDCA-specific. In conclusion, this study supports the possible alteration of arachidonic acid metabolism and PLA2IIA expression level, in particular, as the protective action of UDCA in patients with chronic liver disease. (HEPATOLOGY 2005;41:896–905.)